{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:26:35Z","timestamp":1778221595596,"version":"3.51.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T00:00:00Z","timestamp":1180310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T00:00:00Z","timestamp":1180310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2007,5,28]]},"DOI":"10.1038\/sj.onc.1210370","type":"journal-article","created":{"date-parts":[[2007,5,28]],"date-time":"2007-05-28T10:07:46Z","timestamp":1180346866000},"page":"3704-3713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies"],"prefix":"10.1038","volume":"26","author":[{"given":"J P","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D M","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,28]]},"reference":[{"key":"BF1210370_CR1","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","volume":"20","author":"SM Ansell","year":"2002","unstructured":"Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE . (2002). Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20: 3885\u20133890.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","volume":"328","author":"J Armitage","year":"1993","unstructured":"Armitage J . (1993). Treatment of non-Hodgkin's lymphoma. N Engl J Med 328: 1023\u20131030.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"BF1210370_CR3","first-page":"896","volume":"73","author":"RP Baum","year":"2004","unstructured":"Baum RP, Niesen A, Hertel A, Adams S, Koujouharoff G, Goldenberg DM et al. (2004). Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73 (Suppl 3): 896\u2013899.","journal-title":"Cancer"},{"key":"BF1210370_CR4","first-page":"5771s","volume":"55","author":"WS Becker","year":"1995","unstructured":"Becker WS, Behr TM, Cumme F, Rossler W, Wendler J, Kern PM et al. (1995). 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 55: 5771s\u20135773s.","journal-title":"Cancer Res"},{"key":"BF1210370_CR5","first-page":"32","volume":"3","author":"TM Behr","year":"2002","unstructured":"Behr TM, Holler E, Gratz S . (2002). CD22 is a suitable target molecule for detection and high-dose, myoablative radioimmunotherapy with the monoclonal antibody LL2 in acute lymphatic leukaemia and Waldenstr\u00f6m's macroglobulinemia. Tumor Targeting 3: 32\u201340.","journal-title":"Tumor Targeting"},{"key":"BF1210370_CR6","first-page":"3304s","volume":"5","author":"TM Behr","year":"1999","unstructured":"Behr TM, W\u00f6rmann B, Gramatzki M, Riggert J, Gratz S, Behe M et al. (1999). Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies. Clin Cancer Res 5: 3304s\u201333314s.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR7","first-page":"5764s","volume":"55","author":"MJ Blend","year":"1995","unstructured":"Blend MJ, Hyun H, Kozloff M, Levi H, Mills GQ, Gaspirini M et al. (1995). Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res 55: 5764s\u20135770s.","journal-title":"Cancer Res"},{"key":"BF1210370_CR8","first-page":"6476","volume":"52","author":"DJ Buchsbaum","year":"1992","unstructured":"Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS . (1992). Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52: 6476\u20136481.","journal-title":"Cancer Res"},{"key":"BF1210370_CR9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","volume":"44","author":"J Carnahan","year":"2007","unstructured":"Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ et al. (2007). Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44: 1331\u20131341.","journal-title":"Mol Immunol"},{"key":"BF1210370_CR10","first-page":"3982s","volume":"9","author":"J Carnahan","year":"2003","unstructured":"Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T et al. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9: 3982s\u20133990s.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR11","doi-asserted-by":"crossref","first-page":"350a","DOI":"10.1182\/blood-2001-12-0276","volume":"100","author":"A Cesano","year":"2002","unstructured":"Cesano A, Gayko U, Brannan C . (2002). Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted immunotherapy [abstract]. Blood 100: 350a.","journal-title":"Blood"},{"key":"BF1210370_CR12","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.154.7.3096","volume":"154","author":"N Chaouchi","year":"1995","unstructured":"Chaouchi N, Vazquez A, Calanaud P, Laprince C . (1995). B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol 154: 3096\u20133104.","journal-title":"J Immunol"},{"key":"BF1210370_CR13","doi-asserted-by":"crossref","unstructured":"Chatal J-F, Harousseau J-L, Griesinger F . (2005). Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 Epratuzumab at high cumulative 90Y doses [abstract 447]. Proc Soc Nucl Med, 52nd Annual Meeting, 155P.","DOI":"10.1200\/jco.2004.22.90140.2545"},{"key":"BF1210370_CR14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","volume":"101","author":"BD Cheson","year":"2003","unstructured":"Cheson BD . (2003). Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391\u2013398.","journal-title":"Blood"},{"key":"BF1210370_CR15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00063030-200519050-00004","volume":"19","author":"BD Cheson","year":"2005","unstructured":"Cheson BD . (2005). The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19: 309\u2013322.","journal-title":"BioDrugs"},{"key":"BF1210370_CR16","first-page":"33","volume":"87","author":"KU Chow","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ et al. (2002). Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplstic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87: 33\u201343.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"BF1210370_CR17","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/s00259-003-1157-6","volume":"30","author":"J Coffey","year":"2003","unstructured":"Coffey J, Hodgson DC, Gospodarowicz MK . (2003). Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30 (Suppl 1): S28\u2013S36.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BF1210370_CR18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235\u2013242.","journal-title":"N Engl J Med"},{"key":"BF1210370_CR19","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","volume":"23","author":"B Coiffier","year":"2005","unstructured":"Coiffier B . (2005). State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23: 6387\u20136393.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR20","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. (1998). Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927\u20131932.","journal-title":"Blood"},{"key":"BF1210370_CR21","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"MS Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ . (2004). Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22: 4711\u20134716.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR22","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135\u20133143.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR23","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","volume":"10","author":"TA Davis","year":"2004","unstructured":"Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A et al. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10: 7792\u20137798.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR24","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.4049\/jimmunol.136.12.4470","volume":"136","author":"B D\u00f6rken","year":"1986","unstructured":"D\u00f6rken B, Moldenhauer G, Pezzutto A, Schwartz R, Feller A, Kiesel S et al. (1986). HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136: 4470\u20134479.","journal-title":"J Immunol"},{"key":"BF1210370_CR25","unstructured":"D\u00f6rner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR . (2006). Intitial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8, Apr: 21;8(3):R74 [Epub ahead of print]."},{"key":"BF1210370_CR26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cncr.21606","volume":"106","author":"AD Dosik","year":"2006","unstructured":"Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D et al. (2006). Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106: 616\u2013622.","journal-title":"Cancer"},{"key":"BF1210370_CR27","first-page":"6580","volume":"23","author":"C Emmanouilides","year":"2004","unstructured":"Emmanouilides C, Leonard JP, Schuster SJ . (2004). Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (BLBCL) [abstract]. Proc Am Soc Clin Oncol 23: 6580.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF1210370_CR28","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.4049\/jimmunol.150.11.4719","volume":"150","author":"P Engel","year":"1993","unstructured":"Engel P, Nojima Y, Rothstein D, Zhou LJ, Wilson GL, Kehrl JH et al. (1993). The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils and monocytes. J Immunol 150: 4719\u20134732.","journal-title":"J Immunol"},{"key":"BF1210370_CR29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1084\/jem.181.4.1581","volume":"181","author":"P Engel","year":"1995","unstructured":"Engel P, Wagner N, Miller A, Tedder TF . (1995). Identification of the ligand binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181: 1581\u20131586.","journal-title":"J Exp Med"},{"issue":"1","key":"BF1210370_CR30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2004.1.221","volume":"2004","author":"R. I. Fisher","year":"2004","unstructured":"Fisher RI, Miller TP, O'Connor OA . (2004). Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program), 221\u2013226.","journal-title":"Hematology"},{"key":"BF1210370_CR31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1586\/14737140.4.1.18","volume":"4","author":"JW Friedberg","year":"2004","unstructured":"Friedberg JW, Fisher RI . (2004). Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 4: 18\u201326.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BF1210370_CR32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-0-387-29346-2_5","volume":"131","author":"RR Furman","year":"2006","unstructured":"Furman RR, Coleman M, Muss D, Leonard JP . (2006). Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Cancer Treat Res 131: 141\u2013159.","journal-title":"Cancer Treat Res"},{"key":"BF1210370_CR33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","volume":"4","author":"CJ Gallagher","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS et al. (1986). Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4: 1470\u20131480.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/030089169508100304","volume":"81","author":"M Gasparini","year":"1995","unstructured":"Gasparini M, Bombardieri E, Tondini C, Maffioli L, Hughes L, Burraggi GL et al. (1995). Clinical utility of radioimmunoschintigraphy of non-Hodgkin's lymphoma with radiolabeled LL2 monoclonal antibody, Lymphoscan\u2122; preliminary results. Tumori 81: 173\u2013178.","journal-title":"Tumori"},{"key":"BF1210370_CR35","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. (2004). Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood 103: 4416\u20134423.","journal-title":"Blood"},{"key":"BF1210370_CR36","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. (2000). Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900\u20133908.","journal-title":"Blood"},{"key":"BF1210370_CR37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1040-8428(01)00108-1","volume":"39","author":"DM Goldenberg","year":"2001","unstructured":"Goldenberg DM . (2001). The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 39: 195\u2013201.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF1210370_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00262-002-0348-5","volume":"52","author":"DM Goldenberg","year":"2003","unstructured":"Goldenberg DM . (2003). Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52: 281\u2013296.","journal-title":"Cancer Immunol Immunother"},{"key":"BF1210370_CR39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.1991.9.4.548","volume":"9","author":"DM Goldenberg","year":"1991","unstructured":"Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H et al. (1991). Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 9: 548\u2013564.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR40","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","volume":"5","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R et al. (2004). Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5: 98\u2013101.","journal-title":"Clin Lymphoma"},{"key":"BF1210370_CR41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q","volume":"75","author":"TC Greiner","year":"1995","unstructured":"Greiner TC, Medeiros LJ, Jaffe ES . (1995). Non-Hodgkin's lymphoma. Cancer 75: 370\u2013380.","journal-title":"Cancer"},{"key":"BF1210370_CR42","first-page":"77","volume":"44","author":"GL Griffiths","year":"2003","unstructured":"Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM . (2003). 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44: 77\u201384.","journal-title":"J Nucl Med"},{"issue":"Suppl 12","key":"BF1210370_CR43","first-page":"9","volume":"27","author":"AJ Grillo-Lopez","year":"2000","unstructured":"Grillo-Lopez AJ . (2000). Rituximab: an insider's historical perspective. Semin Oncol 27 (Suppl 12): 9\u201316.","journal-title":"Semin Oncol"},{"key":"BF1210370_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2003.12.005","volume":"31","author":"JD Hainsworth","year":"2004","unstructured":"Hainsworth JD . (2004). Prolonging remission with rituximab maintenance therapy. Semin Oncol 31: 17\u201321.","journal-title":"Semin Oncol"},{"key":"BF1210370_CR45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","volume":"51","author":"A Harjunpaa","year":"2000","unstructured":"Harjunpaa A, Junnikkala S, Meri S . (2000). Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634\u2013641.","journal-title":"Scand J Immunol"},{"key":"BF1210370_CR46","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","volume":"23","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R et al. (2005). Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 23: 6394\u20136399.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","volume":"65","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B . (2005). Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\u00eaB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65: 264\u2013276.","journal-title":"Cancer Res"},{"key":"BF1210370_CR48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics 2006. CA Cancer J Clin 56: 106\u2013130.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"BF1210370_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50025","volume":"30","author":"P Johnson","year":"2003","unstructured":"Johnson P, Glennie M . (2003). The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30 (Suppl 2): 3\u20138.","journal-title":"Semin Oncol"},{"key":"BF1210370_CR50","first-page":"5899s","volume":"55","author":"M Juweid","year":"1995","unstructured":"Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R et al. (1995). Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55: 5899s\u201355907s.","journal-title":"Cancer Res"},{"key":"BF1210370_CR51","first-page":"3292s","volume":"5","author":"ME Juweid","year":"1999","unstructured":"Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S et al. (1999). Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-\/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 5: 3292s\u201333303s.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR52","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","volume":"10","author":"MS Kaminski","year":"1992","unstructured":"Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR et al. (1992). Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10: 1696\u20131711.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. (2005). 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441\u2013449.","journal-title":"N Engl J Med"},{"key":"BF1210370_CR54","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0960-9822(00)00220-7","volume":"4","author":"S Kelm","year":"1994","unstructured":"Kelm S, Pelz A, Schauer R, Filbin MT, Tang S, De Bellard ME et al. (1994). Sialoadhesis, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol 4: 965\u2013972.","journal-title":"Curr Biol"},{"key":"BF1210370_CR55","first-page":"819","volume":"15","author":"RJ Kreitman","year":"1993","unstructured":"Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I . (1993). Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab\u2032 induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res 15: 819\u2013825.","journal-title":"Cancer Res"},{"key":"BF1210370_CR56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/108497802320970307","volume":"17","author":"D Lamonica","year":"2002","unstructured":"Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z . (2002). Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 17: 689\u2013697.","journal-title":"Cancer Biother Radiopharm"},{"key":"BF1210370_CR57","first-page":"17","volume":"151","author":"CL Law","year":"1993","unstructured":"Law CL, Torres RM, Sundberg HA, Parkhouse RM, Brannan CI, Copeland NG et al. (1993). Organization of the murine Cd22 locus. Mapping to chromosome 7 and characterization of two alleles. J Immunol 151: 17\u201387.","journal-title":"J Immunol"},{"issue":"1","key":"BF1210370_CR58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/asheducation-2005.1.335","volume":"2005","author":"J. P. Leonard","year":"2005","unstructured":"Leonard JP . (2005). Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology (Am Soc Hematol Educ Program), 335\u2013339.","journal-title":"Hematology"},{"key":"BF1210370_CR59","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","volume":"23","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR et al. (2005a). Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23: 5044\u20135051.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR60","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"JP Leonard","year":"2003","unstructured":"Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR et al. (2003). Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21: 3051\u20133059.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR61","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","volume":"10","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW et al. (2005b). Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results. Clin Cancer Res 10: 5327\u20135334.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR62","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/0161-5890(95)00080-1","volume":"32","author":"SO Leung","year":"1995","unstructured":"Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB et al. (1995). Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia\/lymphoma antibody, LL2. Mol Immunol 32: 1413\u20131427.","journal-title":"Mol Immunol"},{"key":"BF1210370_CR63","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","volume":"11","author":"O Linden","year":"2005","unstructured":"Linden O, Hindorf C, Cavallin-Stahl E, Wegener WA, Goldenberg DM, Horne H et al. (2005). Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 11: 5215\u20135222.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR64","first-page":"3287s","volume":"5","author":"O Linden","year":"1999","unstructured":"Linden O, Tennvall J, Cavallin-Stahl E, Darte L, Garkavij M, Lindner KJ et al. (1999). Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res 5: 3287s\u20133291s.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/02841860260088854","volume":"41","author":"O Linden","year":"2002","unstructured":"Linden O, Tennvall J, Hindorf C, Cavallin-Stahl E, Lindner KJ, Ohlsson T et al. (2002). 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol 41: 297\u2013303.","journal-title":"Acta Oncol"},{"key":"BF1210370_CR66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A . (2002). Rituximab: mechanism of action and resistance. Semin Oncol 29: 2\u20139.","journal-title":"Semin Oncol"},{"key":"BF1210370_CR67","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR68","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/cncr.22342","volume":"107","author":"INM Micallef","year":"2006","unstructured":"Micallef INM, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP et al. (2006). A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107: 2826\u20132832.","journal-title":"Cancer"},{"key":"BF1210370_CR69","doi-asserted-by":"crossref","first-page":"41a","DOI":"10.1182\/blood.V104.11.41.41","volume":"104","author":"F Morschhauser","year":"2004","unstructured":"Morschhauser F, Huglo D, Martinelli G . (2004). Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial [abstract 130]. Blood 104: 41a.","journal-title":"Blood"},{"key":"BF1210370_CR70","doi-asserted-by":"crossref","first-page":"683a","DOI":"10.1182\/blood.V106.11.683.683","volume":"106","author":"F Morschhauser","year":"2005","unstructured":"Morschhauser F, Leonard JP, Coiffier B . (2005). Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma [abstract]. Blood 106: 683a.","journal-title":"Blood"},{"key":"BF1210370_CR71","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF00177365","volume":"19","author":"S Murthy","year":"1992","unstructured":"Murthy S, Sharkey RM, Goldenberg DM, Lee RE, Pinsky CM, Hansen HJ et al. (1992). Lymphoma imaging with a new technetium-99m labelled antibody, LL2. Eur J Nucl Med 19: 394\u2013401.","journal-title":"Eur J Nucl Med"},{"key":"BF1210370_CR72","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1040-8428(01)00116-0","volume":"39","author":"DL Newton","year":"2001","unstructured":"Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE et al. (2001a). Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. Crit Rev Oncol Hematol 39: 79\u201386.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF1210370_CR73","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood.V97.2.528","volume":"97","author":"DL Newton","year":"2001","unstructured":"Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM . (2001b). Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97: 528\u2013535.","journal-title":"Blood"},{"key":"BF1210370_CR74","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.coi.2005.03.005","volume":"17","author":"L Nitschke","year":"2005","unstructured":"Nitschke L . (2005). The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Op. Immunol 17: 290\u2013297.","journal-title":"Curr Op. Immunol"},{"key":"BF1210370_CR75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-9822(06)00057-1","volume":"7","author":"L Nitschke","year":"1997","unstructured":"Nitschke L, Carsetti B, Ocker B, Kohler G, Lamers MC . (1997). CD22 is a negative regulator of B-cell receptor signaling. Curr Biol 7: 133\u2013143.","journal-title":"Curr Biol"},{"key":"BF1210370_CR76","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1126\/science.274.5288.798","volume":"274","author":"TL O'Keefe","year":"1996","unstructured":"O'Keefe TL, Williams GT, Davies SL, Neuberger MS . (1996). Hyperresponsive B cells in CD22-deficient mice. Science 274: 798\u2013801.","journal-title":"Science"},{"key":"BF1210370_CR77","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/384634a0","volume":"384","author":"KL Otipoby","year":"1996","unstructured":"Otipoby KL, Andersson KB, Draves KE, Klaus SJ, Farr AG, Kerner JD et al. (1996). CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384: 634\u2013637.","journal-title":"Nature"},{"key":"BF1210370_CR78","first-page":"4568","volume":"49","author":"EJ Pawlak-Byczkowska","year":"1989","unstructured":"Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM . (1989). Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 49: 4568\u20134577.","journal-title":"Cancer Res"},{"key":"BF1210370_CR79","first-page":"3995s","volume":"9","author":"EJ Postema","year":"2003","unstructured":"Postema EJ, Raemaekers JM, Oyen WJ, Boerman OC, Mandigers CM, Goldenberg DM et al. (2003). Final results of a phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 9: 3995s\u201334002s.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0093-7754(03)00120-9","volume":"30","author":"OW Press","year":"2003","unstructured":"Press OW . (2003). Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 30: 10\u201321.","journal-title":"Semin Oncol"},{"key":"BF1210370_CR81","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","volume":"7","author":"OW Press","year":"1989","unstructured":"Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R et al. (1989). Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7: 1027\u20131038.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1074-7613(00)80270-8","volume":"5","author":"S Sato","year":"1996","unstructured":"Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang ML et al. (1996). CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5: 551\u2013562.","journal-title":"Immunity"},{"key":"BF1210370_CR83","first-page":"2000","volume":"44","author":"RM Sharkey","year":"2003","unstructured":"Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A et al. (2003). Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44: 2000\u20132018.","journal-title":"J Nucl Med"},{"key":"BF1210370_CR84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/1744666X.1.1.47","volume":"1","author":"RM Sharkey","year":"2005","unstructured":"Sharkey RM, Burton J, Goldenberg DM . (2005). Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Rev Clin Immunol 1: 47\u201362.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 1","key":"BF1210370_CR85","first-page":"115s","volume":"46","author":"RM Sharkey","year":"2005","unstructured":"Sharkey RM, Goldenberg DM . (2005). Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46 (Suppl 1): 115s\u20131127s.","journal-title":"J Nucl Med"},{"key":"BF1210370_CR86","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910560413","volume":"56","author":"LB Shih","year":"1994","unstructured":"Shih LB, Lu HH, Xuan H, Goldenberg DM . (1994). Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56: 538\u2013545.","journal-title":"Int J Cancer"},{"key":"BF1210370_CR87","first-page":"649","volume":"4","author":"JA Siegel","year":"1991","unstructured":"Siegel JA, Goldenberg DM, Sharkey RM . (1991). Tumor and organ dosimetry for I-131 LL2 (EPB2) monoclonal antibody in patients with B-cell lymphomas. Antib Immunconjug Radiopharm 4: 649\u2013654.","journal-title":"Antib Immunconjug Radiopharm"},{"key":"BF1210370_CR88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ctrv.2003.07.006","volume":"30","author":"DH Silverman","year":"2004","unstructured":"Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL . (2004). Radiolabeled antibody therapy in non-Hodgkin's lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 30: 165\u2013172.","journal-title":"Cancer Treat Rev"},{"key":"BF1210370_CR89","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3322\/canjclin.47.6.351","volume":"47","author":"AT Skarin","year":"1997","unstructured":"Skarin AT, Dorfman DM . (1997). Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin 47: 351\u2013372.","journal-title":"CA Cancer J Clin"},{"key":"BF1210370_CR90","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1269\/jrr.46.241","volume":"46","author":"I Skvortsova","year":"2005","unstructured":"Skvortsova I, Popper BA, Skvortsov S, Haidenberger A, Saurer M, Gunkel AR et al. (2005). Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo) 46: 241\u2013248.","journal-title":"J Radiat Res (Tokyo)"},{"key":"BF1210370_CR91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/345074a0","volume":"344","author":"I Stamenkovic","year":"1990","unstructured":"Stamenkovic I, Seed B . (1990). The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 344: 74\u201377.","journal-title":"Nature"},{"key":"BF1210370_CR92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF01518451","volume":"37","author":"R Stein","year":"1993","unstructured":"Stein R, Belisle E, Hansen HJ, Goldenberg DM . (1993). Epitope specificity of the anti-B cell lymphoma monoclonal antibody, LL2. Cancer Immunol Immunother 37: 293\u2013298.","journal-title":"Cancer Immunol Immunother"},{"key":"BF1210370_CR93","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","volume":"10","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Chen S, Rosario A, Horak ID, Hansen HJ et al. (2004). Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10: 2868\u20132878.","journal-title":"Clin Cancer Res"},{"key":"BF1210370_CR94","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1358\/dof.1993.018.11.225256","volume":"18","author":"R Stein","year":"1994","unstructured":"Stein R, Shih LB, Sharkey RM, Hansen HJ, Goldenberg DM . (1994). Immu-RAID\u2122-LL2 [Tc-99\u2009m] and Immu-RAIT\u2122-LL2 [I-131]. Drugs Future 18: 997\u20131004.","journal-title":"Drugs Future"},{"key":"BF1210370_CR95","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/14712598.6.9.943","volume":"6","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Youinou P . (2006). Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert opin Biol Ther 6: 943\u2013949.","journal-title":"Expert opin Biol Ther"},{"key":"BF1210370_CR96","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM et al. (2006). Epratuzumab (humanized anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study. Arthritis Res Ther 8: R129.","journal-title":"Arthritis Res Ther"},{"key":"BF1210370_CR97","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL et al. (2006). Multicenter phase-II trial of immunotherapy with humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24: 3880\u20133886.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(05)88001-0","volume":"88","author":"TF Tedder","year":"2005","unstructured":"Tedder TF, Poe JC, Haas KM . (2005). CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88: 1\u201350.","journal-title":"Adv Immunol"},{"key":"BF1210370_CR99","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H et al. (2004). Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793\u20131800.","journal-title":"Blood"},{"key":"BF1210370_CR100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1387-2656(04)10011-2","volume":"10","author":"CP Theuer","year":"2004","unstructured":"Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC . (2004). Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen. Biotechnol Annu Rev 10: 265\u2013295.","journal-title":"Biotechnol Annu Rev"},{"key":"BF1210370_CR101","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V94.4.1382","volume":"94","author":"JM Tuscano","year":"1999","unstructured":"Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH . (1999). CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK\/SAPK signaling cascade. Blood 94: 1382\u20131393.","journal-title":"Blood"},{"key":"BF1210370_CR102","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1634\/theoncologist.9-2-160","volume":"9","author":"JM Vose","year":"2004","unstructured":"Vose JM . (2004). Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 9: 160\u2013172.","journal-title":"Oncologist"},{"key":"BF1210370_CR103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428190009060322","volume":"38","author":"JM Vose","year":"2000","unstructured":"Vose JM, Colcher D, Gobar L, Bierman PJ, Augustine S, Tempero M et al. (2000). Phase I\/II trial of multiple dose 131I-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma 38: 91\u2013101.","journal-title":"Leuk Lymphoma"},{"key":"BF1210370_CR104","first-page":"267","volume":"43","author":"HN Wagner Jr","year":"2002","unstructured":"Wagner Jr HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM et al. (2002). Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43: 267\u2013272.","journal-title":"J Nucl Med"},{"key":"BF1210370_CR105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.173.1.137","volume":"173","author":"CL Wilson","year":"1991","unstructured":"Wilson CL, Fox CH, Fauci AS, Kehrl JH . (1991). CDNA cloning of the B-cell membrane protein CD22: A mediator of B-B-cell interactions. J Exp Med 173: 137\u2013146.","journal-title":"J Exp Med"},{"key":"BF1210370_CR106","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.4049\/jimmunol.150.11.5013","volume":"150","author":"GL Wilson","year":"1993","unstructured":"Wilson GL, Najfeld V, Kozlow E, Menniger J, Ward D, Kehrl JH . (1993). Genomic structure and chromosomal mapping of the human CD22 gene. J Immunol 150: 5013\u20135024.","journal-title":"J Immunol"},{"issue":"1","key":"BF1210370_CR107","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/asheducation-2004.1.203","volume":"2004","author":"J. N. Winter","year":"2004","unstructured":"Winter JN, Gascoyne RD, Besien KV . (2004). Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program), 203\u2013220.","journal-title":"Hematology"},{"key":"BF1210370_CR108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1358\/dot.2004.40.2.799423","volume":"40","author":"TE Witzig","year":"2004","unstructured":"Witzig TE . (2004). Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barcelona) 40: 111\u2013119.","journal-title":"Drugs Today (Barcelona)"},{"key":"BF1210370_CR109","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"BF1210370_CR110","first-page":"357a","volume":"100","author":"AD Zelenetz","year":"2002","unstructured":"Zelenetz AD, Vose J . (2002). Patients with transformed low-grade lymphoma attain durable responses following outpatient radioimmunotherapy with toxitumomab and iodine I-131 toxitumomab (Bexxar) [abstract]. Blood 100: 357a.","journal-title":"Blood"},{"issue":"Part 2","key":"BF1210370_CR111","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminoncol.2005.01.008","volume":"32","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL . (2005). Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 32 (Part 2): 4\u201310.","journal-title":"Semin Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1210370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210370","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1210370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:36:45Z","timestamp":1683855405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1210370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,28]]},"references-count":111,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2007,5,28]]}},"alternative-id":["BF1210370"],"URL":"https:\/\/doi.org\/10.1038\/sj.onc.1210370","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,28]]},"assertion":[{"value":"28 May 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}